Mark J. Forchette Named President and Chief Executive Officer of OptiMedica Corporation
Mr. Forchette has 23 years of Ophthalmic sales, marketing and business unit management experience. Immediately prior to OptiMedica, he led the Alcon vitreoretinal business unit as Vice President of Global Marketing and Sales. In this leadership position, Mark managed Alcon's 300 million dollar vitreoretinal business unit through a period of substantial portfolio enhancements, infrastructure development and significant market share increases. Prior to Alcon, he was Vice President of Sales and Marketing at Grieshaber & Co. Inc., and directed the privately held Swiss ophthalmic company domestic operations through significant revenue growth, infrastructure expansion and ultimately acquisition by Alcon. Mark received a BS degree in Marketing from Auburn University and completed the Harvard Program for Management Development.
"The Board of Directors is extremely pleased to welcome Mark as CEO of OptiMedica," stated Brook Byers, Chairman of the Board and Partner of Kleiner Perkins Caufield & Byers. "OptiMedica is in an important growth period as an organization, and the appointment of Mark as CEO and his participation on the Board of Directors is a critical next step in our strategic plan."
Forchette commented, "I am very excited about joining OptiMedica and appreciate the opportunity to lead the company into the future. The Pattern Scanning Laser currently on the market is breakthrough technology and represents our first step in delivering innovations that enhance patient care. The high caliber talent within the team, combined with the current technology, intellectual property and development projects underway, create an extraordinary opportunity for significant growth. Our objectives are to focus on improving patient outcomes through delivery of remarkable performance driven technologies and to support ophthalmologists with uncompromised customer care."
About OptiMedica
OptiMedica Corp. develops and markets performance driven ophthalmic technologies focused on improving patient outcomes. OptiMedica holds the exclusive license to the Pascal® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are FDA approved to treat a variety of retinal conditions. OptiMedica was founded 2004 in Santa Clara, Calif. and is funded by Kleiner Perkins Caufield & Byers and Alloy Ventures. For more information, please visit www.optimedica.com.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5423891
Contact: for OptiMedica Corp. Ellen Topp, +1 415-591-4048 ellen.topp@bm.com
Source: OptiMedica Corp.